Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Dicerna brings in $29mm through its Series B venture round

Executive Summary

Dicerna Pharmaceuticals Inc. (RNA interference therapeutics) has raised $25mm through its Series B venture round. New backer Domain Associates led (and contributes a board member) and was joined by current shareholders Oxford Bioscience Partners, Skyline Ventures, and Abingworth. Dicerna will use some of the proceeds to develop conjugated drug delivery systems, move its lead cancer program into the clinic, and work on its other preclinical drug candidates.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Site Specific
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
    • Nanotechnology, Chips, etc.
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies